ERBB2 and breast cancer: Recurrence and survival rates vary among BC subtypes, with triple-negative BC [negative estrogen receptor (ER), progesterone receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2)] as the most aggressive subtype (2).